Skip to main content
PharmaResources (Shanghai) Co., Ltd. logo

PharmaResources (Shanghai) Co., Ltd. — Investor Relations & Filings

Ticker · 301230 ISIN · CNE1000065Q9 Shenzhen Stock Exchange Professional, scientific and technical activities
Open in API
Filings indexed 458 across all filing types
Latest filing 2022-12-30 Governance Information
Country CN China
Listing Shenzhen Stock Exchange 301230

About PharmaResources (Shanghai) Co., Ltd.

https://www.pharmaresources.cn

PharmaResources (Shanghai) Co., Ltd. is a comprehensive Contract Research Organization (CRO) and Contract Development and Manufacturing Organization (CDMO) specializing in small molecule drug discovery and development. The company provides an integrated platform of services including medicinal chemistry, custom synthesis, process research and development, and analytical chemistry. PharmaResources supports global pharmaceutical and biotechnology partners through the entire drug development lifecycle, from initial lead optimization to the commercial-scale manufacturing of advanced intermediates and Active Pharmaceutical Ingredients (APIs). With a focus on technical innovation and quality management, the firm utilizes advanced synthetic methodologies and process engineering to accelerate drug candidates toward clinical trials and market approval.

Recent filings

Filing Released Lang Actions
监事会议事规则
Governance Information Classification · 100% confidence The document is titled as the "Rules of Procedure for the Supervisory Board Meetings" of Shanghai Hongbo Zhiyuan Pharmaceutical Co., Ltd. It details the governance procedures, meeting notices, proposal submissions, voting rules, and record-keeping for the supervisory board. There is no financial data, no mention of financial results, no earnings, no capital changes, no legal proceedings, no voting results, and no announcements of reports. The content is focused on internal governance rules and procedures for the supervisory board, which aligns with governance information about the company's internal rules and board structure. The document length is 3811 characters, which is relatively short but contains substantive governance content rather than a mere announcement. Therefore, the appropriate classification is Governance Information (CGR).
2022-12-30 Chinese
董事会议事规则
Governance Information Classification · 100% confidence The document is titled '董事会议事规则' which translates to 'Board Meeting Rules' or 'Rules of Procedure for the Board of Directors' of Shanghai Hongbo Zhiyuan Pharmaceutical Co., Ltd. The content details the procedures, rules, and governance related to the board meetings, including meeting notices, proposal submissions, voting procedures, attendance, and record-keeping. It references relevant laws and regulations governing board operations. This document is a governance-related document outlining internal rules and board structure rather than a financial report, announcement, or other filing types. Therefore, it fits the category of Governance Information (CGR). The document length is over 6,000 characters and contains detailed procedural content, confirming it is not a brief announcement or a certification but a substantive governance document.
2022-12-30 Chinese
关于持股5%以上股东部分股份质押的公告
Major Shareholding Notification Classification · 100% confidence The document is an announcement regarding the pledge of shares by a shareholder holding more than 5% of the company's shares. It details the number of shares pledged, the proportion of shares pledged relative to total holdings and company capital, and confirms no risk of control change or forced transfer. The document is a regulatory disclosure about a shareholder's share pledge, which fits the category of Major Shareholding Notification (MRQ) since it involves a significant shareholder's share pledge information. The document length is short and focused on this specific shareholder event, not a full financial report or other types of filings.
2022-12-06 Chinese
上海泓博智源医药股份有限公司首次公开发行股票并在创业板上市之上市公告书提示性公告
Regulatory Filings Classification · 95% confidence The document is titled as a "上市公告书提示性公告" which translates to a "Listing Announcement Notice" related to the company's initial public offering (IPO) and listing on the Shenzhen Stock Exchange's Growth Enterprise Market (创业板). It includes details about the stock code, number of shares issued, pricing, risk warnings, and contact information. The document explicitly states that the full listing announcement and prospectus are available on official disclosure websites, indicating this document is a summary or notice rather than the full prospectus or financial report. The document length is relatively short (2852 characters), and it serves as an announcement of the listing event rather than a detailed financial report or prospectus. Therefore, it fits best into the category of Regulatory Filings (RNS) as a general regulatory announcement that does not fit into other specific categories like Annual Report, Capital Update, or Proxy Statement.
2022-10-30 Chinese
北京市嘉源律师事务所关于上海泓博智源医药股份有限公司首次公开发行股票于深圳证券交易所创业板上市之法律意见书
Regulatory Filings
2022-10-30 Chinese
中信证券股份有限公司关于上海泓博智源医药股份有限公司首次公开发行股票并在创业板上市之上市保荐书
Regulatory Filings Classification · 95% confidence The document is a detailed listing sponsorship letter (上市保荐书) from CITIC Securities for Shanghai Hongbo Zhiyuan Pharmaceutical Co., Ltd. regarding its initial public offering (IPO) and listing on the ChiNext board of the Shenzhen Stock Exchange. It contains extensive company background, business overview, core technologies, financial data for multiple years, risk factors, and compliance statements. The document is not a typical financial report like an annual or quarterly report, nor is it an earnings release or a call transcript. It is a formal regulatory filing related to the IPO process, providing comprehensive information required for the stock listing approval. This type of document fits best under Regulatory Filings (RNS) as it is a regulatory announcement and compliance document for the IPO, not a financial report or presentation. The document length (15,000 characters) and content confirm it is not a brief announcement or a report publication notice but a substantive regulatory filing.
2022-10-30 Chinese

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.